OTLK 外匯新聞
Outlook Therapeutics Says UK MHRA Grants Marketing Authorization For LYTENAVA To Treat Wet AMD
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for LYTENAVA (bevacizumab gamma).
RTTNews
|
115天前
Outlook Therapeutics Announces Receipt Of Type A Meeting Official Minutes On ONS-5010 BLA
Biopharmaceutical company Outlook Therapeutics, Inc. (OTLK) announced Monday the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA) held in October 2023.
RTTNews
|
339天前
